TARGET LABYRINTHIN* TO CURE CANCER

LabyRx has patents pending on a novel cancer marker and therapeutic target called Labyrinthin*.  Our lead product, LabVax, is a Labyrinthin-derived synthetic peptide vaccine that recruits the body's immune cells to attack adenocarcinomas cancers,  which represent approximately 40% of all cancers and 75% of all cancer deaths.

LabyRx Our Vision Image (Masked_Blue).pn

OUR VISION

We are passionate about finding a cure for cancer. Our goal is to bring novel therapies harnessing our body's own immune system to treat patients suffering from a wide range of adenocarcinoma cancers. We have built and continue to expand a team of talented and motivated people to pursue our collective mission.